Table 1

Baseline characteristics of study patients by treatment group

CharacteristicEtanercept group (n=40)Sulfasalazine group (n=36)All patients (n=76)
Age in years, mean (±SD)34.5 (8.6)32.8 (8.4)33.7 (8.5)
Disease duration (back pain duration) in years, mean (±SD)2.6 (1.7)3.0 (1.8)2.9 (1.7)
Male patients, n (%)23 (57.5)21 (58.3)44 (57.9)
HLA-B27 positive, n (%)34 (85)28 (77.8)62 (81.6)
Elevated CRP (CRP >5 mg/l), n (%)24 (60.0)16 (44.4)40 (52.6)
Clinical arthritis, n (%)15 (37.5)18 (50.0)33 (43.4)
Clinical enthesitis, n (%)25 (62.5)24 (66.7)49 (64.5)
Fulfilled New York criteria, n (%)2020 (50)19 (52.8)39 (51.3)
  • For further baseline data see tables 2 and 3.

  • CRP, C-reactive protein (reference range <5mg/l).